Logo do repositório
 
Publicação

Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease?

2020Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorBarros, Raquel
dc.contributor.authorCamões De Araújo, Patrícia
dc.contributor.authorMourato, Cláudia
dc.contributor.authorBudzak, Khrystyna
dc.contributor.authorOliveira, Ana
dc.contributor.authorBárbara, Cristina
dc.date.accessioned2021-01-06T14:23:24Z
dc.date.available2021-01-06T14:23:24Z
dc.date.issued2020
dc.description© 2020 Eurasian Journal of Pulmonology Published by Wolters Kluwer - Medknow.pt_PT
dc.description.abstractIntroduction: Currently, the bronchodilator reversibility is not recommended to differentiate asthma from chronic obstructive pulmonary disease (COPD); however, physiopathological specificities of each disease contribute to the differences in response to the drug. Objectives: The objective of this study is to evaluate the differences in bronchodilator response between asthmatic and COPD patients and to determine which of the bronchodilation criteria have the best ability to detect the positive response in these patients. Materials and methods: This was a cross-sectional study. The sample included 104 patients with asthma or COPD who performed lung function tests between January and March 2018. The whole sample was analyzed according to postbronchodilator variation (Δ) of lung function parameters, and the postbronchodilator reversibility was characterized using a multiple bronchodilation criteria. The drug used in reversibility test was salbutamol. Results: In this study, Δ forced-expiratory volume in the 1st s (ΔFEV1) and a Δ Raw was statistically higher in the group with asthma compared with the group with COPD. In the asthma group, the criteria ↓ functional residual capacity (FRC) ≥10%, ↓Raw ≥ 35%, ↑ forced expiratory flow between 25% and 75% of vital capacity (FEF25%–75%) ≥20% and ↑ FEV1 and / or ↑ forced vital capacity ≥12% and 200 mL were those that presented a greater capacity of detecting a positive response to bronchodilator. The criteria ↑ FEF25%–75%≥20% and ↓ FRC ≥ 10% were those that had the greater ability of detecting airway reversibility in COPD group. Conclusion: The analysis of postbronchodilator FEV1 and raw modifications as well as the using of a combination of multiple bronchodilation criteria contribute to a deeper characterization of bronchodilator reversibility in asthma and COPD.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEurasian J Pulmonol 2020;22:169-74pt_PT
dc.identifier.doi10.4103/ejop.ejop_16_20pt_PT
dc.identifier.eissn2148-5402
dc.identifier.issn2148-3620
dc.identifier.urihttp://hdl.handle.net/10451/45685
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWolters Kluwerpt_PT
dc.relation.publisherversionhttps://www.eurasianjpulmonol.com/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/pt_PT
dc.subjectAsthmapt_PT
dc.subjectBronchodilation criteriapt_PT
dc.subjectBronchodilator responsept_PT
dc.subjectChronic obstructive pulmonary diseasept_PT
dc.titleBronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease?pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue3pt_PT
oaire.citation.startPage169pt_PT
oaire.citation.titleEurasian Journal of Pulmonologypt_PT
oaire.citation.volume22pt_PT
person.familyNameBarros
person.familyNameCamões de Araújo
person.familyNameBudzak
person.familyNameOliveira
person.familyNameBárbara
person.givenNameRaquel
person.givenNamePatrícia
person.givenNameKhrystyna
person.givenNameAna
person.givenNameCristina
person.identifier1330713
person.identifier.ciencia-id171F-DE21-B23B
person.identifier.orcid0000-0003-1712-028X
person.identifier.orcid0000-0002-5640-7518
person.identifier.orcid0000-0002-1254-8175
person.identifier.orcid0000-0001-6522-0985
person.identifier.orcid0000-0003-0915-4105
person.identifier.scopus-author-id6701574502
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb54cf30a-31e0-42f9-b34f-b9409dbea9cf
relation.isAuthorOfPublicationcc884798-8331-411e-ab10-a822b1e932cd
relation.isAuthorOfPublication832dfe12-086c-4ed7-892b-c3705afa2606
relation.isAuthorOfPublicationfa041a12-04fb-4f0e-8ae4-478ec19e18cf
relation.isAuthorOfPublicationa16c0cb5-c7f4-4cca-b9f9-bbeb6d35c474
relation.isAuthorOfPublication.latestForDiscoveryb54cf30a-31e0-42f9-b34f-b9409dbea9cf

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Bronchodilator_reversibility.pdf
Tamanho:
916.48 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

FM - Artigos em Revistas Internacionais